argenx R&D Day 2021  

argenx R&D Day 2021

Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET)

argenx hosted a virtual R&D Day to highlight its ‘argenx 2025 vision’ and provide an update of its immunology pipeline. Visit the R&D Day website to listen to the replay of this event and consult more additional bonus content.

The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.

The infinity sign symbolizes our commitment to science and patients; it has no bounds.

Infinity argenx


argenx infinity



Where we operate

Together We Discover

We know that leaps in progress will come from collaboration and incorporating innovation into every step. We embrace the power of the collective – together we are better.

Our Discoveries

At argenx, we’ve created an antibody innovation ecosystem where pioneering scientists and antibody engineers work side-by-side to accelerate the discovery of novel targets, disease pathways and differentiated therapeutic antibodies.


Doing the Unthinkable

argenx comes from the story of the Argonauts – we want to achieve the unthinkable together.

Dare To Do More

We dare you to see where argenx can take your career next.


Product Candidates

Our proprietary portfolio is focused on first-in-class product candidates engineered in collaboration with our academic partners to help translate immunology breakthroughs into medicines.

Our Pride



We are investigating efgartigimod for the treatment of myasthenia gravis and other severe autoimmune diseases.

Designed to block FcRn and reduce IgGs, efgartigimod could be a rational approach to treating diseases where IgG antibodies are pathogenic or disease-causing.


Phase 3



We are evaluating ARGX-117 for the treatment of severe IgM driven auto-immune diseases. Multifocal motor neuropathy is the first indication selected.

ARGX-117 is designed to be a humanized sweeping antibody intended to inhibit the function of C2 and downstream complement activation.


Phase 1